 Cumberland Pharmaceuticals Inc. NASDAQ: CPIX, a U.S. specialty pharmaceutical company announces two new publications detailing the sustained in vitro potency of Vibativ telavancin as part of a 7-year antimicrobial surveillance program. Both publications were part of continued surveillance of telavancin activity since 2011. The first publication tested a global collection of 24,408 Gram-positive clinical isolates, and the second publication tested a U.S. collection of 15,882 S. aureus isolates. All isolates were collected from the SENTRY Antimicrobial Surveillance Program. 